Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart system helps nurses and doctors stop dangerous low blood sugar in its tracks

NCT ID NCT07314749

Disease control Sponsor: Third Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a team of doctors and nurses, guided by an intelligent early-warning system, could reduce low blood sugar (hypoglycemia) in hospitalized adults with type 2 diabetes. Over 1,200 participants received either standard insulin pump therapy or the same therapy plus the collaborative intervention, which included personalized insulin adjustments and risk-based education. The goal was to see if the smart system could help prevent hypoglycemia and help patients reach their blood sugar targets faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Physician-nurse collaborative intervention guided by an intelligent hypoglycemia risk early-warning system
What this could lead to
If successful, this approach could help hospitals prevent dangerous low blood sugar episodes and help patients with type 2 diabetes reach their blood sugar targets faster during insulin pump therapy.
What could go wrong
This is a completed study, but its findings may not apply to all diabetes patients, especially those not hospitalized or on different treatments. The intelligent system's accuracy and generalizability need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,255 people

The number who actually took part.

Started

Feb 2023

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with type 2 diabetes mellitus. * Age 18 years or older. * Hospitalized for 3 days or longer. * Receiving continuous subcutaneous insulin infusion (CSII) therapy during hospitalization. Exclusion Criteria: * Acute diabetic complications (e.g., diabetic ketoacidosis, hyperosmolar hyperglycemic state). * Severe cardiovascular or cerebrovascular disease, hepatic dysfunction, or renal dysfunction. * Malignant tumors. * Severe cognitive impairment or psychiatric disorders that prevent cooperation. * Premature discontinuation of CSII therapy due to non-glycemic reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypoglycemia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Third Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510630, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.